Amarin (AMRN) Aperçu de l'action
Amarin Corporation plc, une société pharmaceutique, se consacre à la commercialisation et au développement de produits thérapeutiques pour le traitement des maladies cardiovasculaires aux États-Unis, en Europe et dans le monde entier. Plus de détails
| Score flocon de neige | |
|---|---|
| Évaluation | 5/6 |
| Croissance future | 3/6 |
| Performances passées | 0/6 |
| Santé financière | 6/6 |
| Dividendes | 0/6 |
Récompenses
Analyse des risques
Aucun risque n'a été détecté pour AMRN à partir de nos contrôles de risques.
AMRN Community Fair Values
Create NarrativeSee what 14 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Amarin Corporation plc Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | US$14.56 |
| Plus haut sur 52 semaines | US$20.90 |
| Plus bas sur 52 semaines | US$10.34 |
| Bêta | 0.82 |
| Variation sur 1 mois | -4.21% |
| Variation sur 3 mois | -1.22% |
| Variation sur 1 an | 37.62% |
| Variation sur 3 ans | -43.13% |
| Variation sur 5 ans | -84.04% |
| Évolution depuis l'introduction en bourse | -99.88% |
Nouvelles et mises à jour récentes
Mise à jour du récit • Apr 24
AMRN: Guideline Endorsements And Execution Risks Will Limit Future Share Returns
Analysts have maintained their fair value estimate for Amarin at $12.00. They made only minor adjustments to assumptions such as the discount rate and future P/E, which resulted in no change to the updated price target.Mise à jour du récit • Apr 08
AMRN: Guideline Support And Flat Earnings Outlook Will Restrain Future Upside
Narrative Update on Amarin Amarin's updated analyst price target holds steady at $12.00, as analysts point to only very small adjustments in discount rate, revenue growth assumptions, profit margin and future P/E that do not materially change their overall valuation view. Analyst Commentary Analysts covering Amarin are generally treating the current valuation as balanced, with the updated US$12.00 price target reflecting only modest tweaks to their core assumptions rather than a major shift in outlook.Recent updates
Mise à jour du récit • Apr 24
AMRN: Guideline Endorsements And Execution Risks Will Limit Future Share Returns
Analysts have maintained their fair value estimate for Amarin at $12.00. They made only minor adjustments to assumptions such as the discount rate and future P/E, which resulted in no change to the updated price target.Mise à jour du récit • Apr 08
AMRN: Guideline Support And Flat Earnings Outlook Will Restrain Future Upside
Narrative Update on Amarin Amarin's updated analyst price target holds steady at $12.00, as analysts point to only very small adjustments in discount rate, revenue growth assumptions, profit margin and future P/E that do not materially change their overall valuation view. Analyst Commentary Analysts covering Amarin are generally treating the current valuation as balanced, with the updated US$12.00 price target reflecting only modest tweaks to their core assumptions rather than a major shift in outlook.Mise à jour du récit • Mar 25
AMRN: Guideline Tailwinds And Earnings Assumptions Will Limit Future Upside Potential
Amarin's updated analyst price target holds steady at $12.00, with analysts pointing to only marginal tweaks in the discount rate and long-term P/E assumptions as they refine their valuation framework rather than rethink the story. Analyst Commentary Analysts covering Amarin are keeping the updated US$12.00 target steady, framing recent tweaks as fine tuning of their models rather than a shift in the fundamental view on the company.Mise à jour du récit • Mar 11
AMRN: Index Removal And Weaker Margins Will Restrict Future Upside Potential
Analysts have revised their price target on Amarin to $12.00, reflecting updated assumptions for revenue trends, profit margins, the discount rate, and a higher future P/E multiple in their models. Analyst Commentary Analysts revising their models for Amarin are focusing on how updated revenue and margin assumptions, along with the use of a higher P/E multiple, translate into the new US$12.00 price target.Mise à jour du récit • Feb 25
AMRN: Index Removal And Execution Risks Will Limit Future Upside Potential
Analysts have modestly adjusted their price target on Amarin, keeping fair value around $12.00. Small tweaks to the discount rate and future P/E assumptions refine their view rather than signal a major shift in the story.Mise à jour du récit • Feb 11
AMRN: Index Removal And Execution Risks Will Continue To Limit Upside
Analysts have adjusted their price target for Amarin to US$12.00. They attribute this move to slightly higher assumed discount rates, a modest tweak to long term revenue and margin expectations, and a small uplift in future P/E assumptions.Mise à jour du récit • Jan 27
AMRN: Index Removal And Execution Risks Will Constrain Future Upside Potential
Analysts have reaffirmed Amarin's fair value at US$12.00 per share, citing only modest tweaks to discount rate, revenue growth, profit margin and future P/E assumptions, rather than a change in their overall view of the stock. Analyst Commentary Analysts are largely using the reaffirmed US$12.00 fair value as a reference point to stress test their assumptions on growth, profitability and execution risk for Amarin, rather than to rethink the overall thesis.Mise à jour du récit • Jan 12
AMRN: Index Removal And Weakening Revenue Outlook Will Constrain Future Upside Potential
Analysts have kept their fair value estimate for Amarin steady at US$12.00 per share, with only minor model tweaks to the discount rate, revenue trajectory and expected P/E that help to fine tune rather than shift their overall price target view. What's in the News Amarin issued revenue guidance for the fourth quarter of 2025, expecting net revenue of US$48 million to US$53 million, and for the full year 2025, expecting net revenue of US$212 million to US$217 million (corporate guidance).Article d’analyse • Dec 10
Companies Like Amarin (NASDAQ:AMRN) Are In A Position To Invest In Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Mise à jour du récit • Dec 10
AMRN: Pricing And Competitive Pressures Will Likely Limit Future Upside Potential
Analysts have modestly lifted their price target on Amarin to $12.00 from $12.00. This reflects steady assumptions around long term discount rates, revenue growth, profit margins, and future earnings multiples despite a still cautious backdrop for the broader sector.Mise à jour du récit • Nov 26
AMRN: Rising Competitive Pressures Will Likely Challenge Future Profit Margin Expansion
Amarin's analyst price target has increased from $11.00 to $12.00. This reflects analysts' expectations of improved revenue growth and a notably stronger profit margin outlook for the company.Article d’analyse • Oct 04
Amarin Corporation plc (NASDAQ:AMRN) Stock Catapults 25% Though Its Price And Business Still Lag The Industry
Amarin Corporation plc ( NASDAQ:AMRN ) shares have had a really impressive month, gaining 25% after a shaky period...Article d’analyse • Jun 12
Amarin Corporation plc (NASDAQ:AMRN) Shares Fly 27% But Investors Aren't Buying For Growth
Amarin Corporation plc ( NASDAQ:AMRN ) shares have continued their recent momentum with a 27% gain in the last month...Article d’analyse • Jun 12
We Think Amarin (NASDAQ:AMRN) Can Afford To Drive Business Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Seeking Alpha • Jun 06
Amarin Is A Sell Despite The Large Cash Balance
Summary Amarin's Vascepa drug had initial commercial success but is now facing steep revenue declines due to generic competition and limited U.S. market adoption. The company is running sizable losses, with operating expenses exceeding product revenues, and European launches have not offset U.S. declines. Amarin trades below its cash value, providing some margin of safety and potential M&A appeal, but ongoing cash burn will erode this over time. Given the lack of clear catalysts and persistent losses, I expect Amarin to generate negative returns unless strategic action occurs soon. Read the full article on Seeking Alpha
Nouveau récit • Apr 01
I Foresee 49 Approvals Driving European And Global Market Expansion
Expanded regulatory approvals and commercialization in 49 markets support future revenue growth, particularly through focused expansion in Europe and worldwide.Article d’analyse • Mar 15
The Market Doesn't Like What It Sees From Amarin Corporation plc's (NASDAQ:AMRN) Revenues Yet As Shares Tumble 26%
Amarin Corporation plc ( NASDAQ:AMRN ) shares have had a horrible month, losing 26% after a relatively good period...Article d’analyse • Jan 24
Amarin Corporation plc (NASDAQ:AMRN) Held Back By Insufficient Growth Even After Shares Climb 39%
Amarin Corporation plc ( NASDAQ:AMRN ) shareholders would be excited to see that the share price has had a great month...Article d’analyse • Jan 03
Here's Why We're Not Too Worried About Amarin's (NASDAQ:AMRN) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Article d’analyse • Oct 29
Little Excitement Around Amarin Corporation plc's (NASDAQ:AMRN) Revenues
You may think that with a price-to-sales (or "P/S") ratio of 1x Amarin Corporation plc ( NASDAQ:AMRN ) is definitely a...Article d’analyse • Aug 01
Amarin Corporation plc (NASDAQ:AMRN) Shares Could Be 29% Above Their Intrinsic Value Estimate
Key Insights Using the 2 Stage Free Cash Flow to Equity, Amarin fair value estimate is US$0.53 Amarin's US$0.68 share...Article d’analyse • Jun 06
Amarin Corporation plc's (NASDAQ:AMRN) 28% Dip In Price Shows Sentiment Is Matching Revenues
The Amarin Corporation plc ( NASDAQ:AMRN ) share price has fared very poorly over the last month, falling by a...Seeking Alpha • Apr 16
Amarin Corporation: Small Signs Of Recovery May Not Be Enough
Summary Amarin is going through a turbulent period with a strong contraction in revenue and margins. The EU and China markets seem too small to make significant changes, and the US market is suffering from margin erosion. The number of hedge funds that are investing in Amarin is reducing. My share price evaluation does not seem to offer positive returns on investment. Read the full article on Seeking AlphaArticle d’analyse • Mar 12
Little Excitement Around Amarin Corporation plc's (NASDAQ:AMRN) Revenues As Shares Take 27% Pounding
Amarin Corporation plc ( NASDAQ:AMRN ) shares have retraced a considerable 27% in the last month, reversing a fair...Seeking Alpha • Jan 15
Amarin: Sarissa Is Giving Me Hope Again
Summary Sarissa Capital is successfully turning around Amarin, giving it new life and potential for success. Amarin's REDUCE-IT trial proved the cardiovascular benefits of its purified EPA product, Vascepa, leading to its potential for greatness. The implementation of strategic proposals, a new CEO with relevant expertise, and higher than expected Q4 earnings are positive signs for Amarin's future. Read the full article on Seeking AlphaArticle d’analyse • Jan 03
Improved Revenues Required Before Amarin Corporation plc (NASDAQ:AMRN) Stock's 26% Jump Looks Justified
Amarin Corporation plc ( NASDAQ:AMRN ) shareholders would be excited to see that the share price has had a great month...Article d’analyse • Nov 19
Calculating The Fair Value Of Amarin Corporation plc (NASDAQ:AMRN)
Key Insights The projected fair value for Amarin is US$0.95 based on 2 Stage Free Cash Flow to Equity Current share...Rendement pour les actionnaires
| AMRN | US Biotechs | US Marché | |
|---|---|---|---|
| 7D | -3.3% | -1.6% | -0.9% |
| 1Y | 37.6% | 34.4% | 24.4% |
Rendement vs Industrie: AMRN a sous-performé le secteur US Biotechs qui a rapporté 34.4 % au cours de l'année écoulée.
Rendement vs marché: AMRN a dépassé le marché US qui a rapporté 24.4 % au cours de l'année écoulée.
Volatilité des prix
| AMRN volatility | |
|---|---|
| AMRN Average Weekly Movement | 6.0% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.1% |
Cours de l'action stable: AMRN n'a pas connu de volatilité de prix significative au cours des 3 derniers mois par rapport au marché US.
Volatilité au fil du temps: La volatilité hebdomadaire de AMRN ( 6% ) est restée stable au cours de l'année écoulée.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| 1989 | 80 | Aaron Berg | www.amarincorp.com |
Amarin Corporation plc, société pharmaceutique, commercialise et développe des produits thérapeutiques pour le traitement des maladies cardiovasculaires aux États-Unis, en Europe et dans le monde entier. Elle propose VASCEPA, un produit à base d'acides gras oméga-3 délivré sur ordonnance, utilisé en complément d'un régime alimentaire pour réduire les taux de triglycérides chez les patients adultes souffrant d'hypertriglycéridémie sévère. La société vend ses produits principalement par l'intermédiaire de grossistes, de grossistes régionaux sélectionnés, de détaillants et de pharmacies de vente par correspondance.
Amarin Corporation plc Résumé des fondamentaux
| AMRN statistiques fondamentales | |
|---|---|
| Capitalisation boursière | US$309.92m |
| Bénéfices(TTM) | -US$33.61m |
| Recettes(TTM) | US$216.76m |
1.4x
Ratio P/S-9.1x
Ratio P/ELe site AMRN est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| AMRN compte de résultat (TTM) | |
|---|---|
| Recettes | US$216.76m |
| Coût des recettes | US$103.25m |
| Marge brute | US$113.51m |
| Autres dépenses | US$147.12m |
| Les revenus | -US$33.61m |
Derniers bénéfices déclarés
Mar 31, 2026
Prochaine date de publication des résultats
s/o
| Résultat par action (EPS) | -1.60 |
| Marge brute | 52.36% |
| Marge bénéficiaire nette | -15.51% |
| Ratio dettes/capitaux propres | 0% |
Quelles ont été les performances à long terme de AMRN?
Voir les performances historiques et les comparaisonsAnalyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/05/15 11:01 |
| Cours de l'action en fin de journée | 2026/05/15 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Amarin Corporation plc est couverte par 19 analystes. 2 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Ritu Baral | Canaccord Genuity |
| Andrew Fein | Chardan Capital Markets, LLC |
| John Boris | Citigroup Inc |